Table 3.
Characteristics of studies included in the systematic review
| Study | Reference | Year of publication | Study design | Patients number | FIGO Stage | Early stage (%) | Advanced stage (%) | Type of epithelial Ovarian cancer (%) | Intervention | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Matsuhashi et al.(31) | 2017 | Retrospective | 110 | III-IV | 0 | 100.0 | Serous 78.5 Mucinous 2.8 Endometroid 4.7 Clear cell 11.2 Undifferentiated 4.7 | NACT-IDS | |
| 2 | Prajatmoet al.(28) | 2016 | Prospective | 90 | I-IV | 38.9 | 61.1 | Serous 27.8 Mucinous 48.9 Others 23.4 | NACT-IDS | |
| 3 | Gupta et al.(38) | 2020 | Retrospective | 433 | III-IV | 0 | 100.0 | Serous 95.5 Others 4.5 | NACT-IDS | |
| 4 | Parashkevovaet al.(36) | 2018 | Retrospective | 111 | II-IV | 3.6 | 96.3 | Serous 100.0 | SCS | |
| 5 | May et al. (34) | 2017 | Retrospective | 212 | I-IV | 11.3 | 88.7 | Serous 100.0 | PDS | |
| 6 | Muallem et al.(35) | 2017 | Prospective | 277 | II-IV | 3.1 | 96.9 | Serous 100.0 | PDS | |
| 7 | Bachmann et al.(29) | 2020 | Retrospective | 261 | IIIA-IV | 0 | 100.0 | Serous 100.0 | PDS | |
| 8 | Merlo et al. (32) | 2021 | Retrospective | 253 | IIIC-IV | 0 | 100.0 | Serous 92.5 | NACT-IDS | |
| 9 | Bai et al.(33) | 2016 | Retrospective | 375 | I-IV | 56.5 | 43.5 | Clear cell 100.0 | PDS |